Stop TB Partnership

Information on Delamanid

In 2016, the StopTB Partnership and Otsuka announced an innovative public-private partnership to allow all countries eligible for financing TB activities through the Global Fund to access delamanid through the Global Drug Facility.

Delamanid is approved by a Stringent Regulatory Authority (European Medicines Agency [EMA] and Japan).

Please see the latest guidelines and rapid communications from the World Health Organization’s Global TB Programme for more information on the role of delamanid in the treatment of TB.

Information on how to procure delamanid pure drug substance for drug susceptibility testing are available in this FAQ (point 3.10).

If you need to report an adverse event related to delamanid, please follow instruction in here.

For an update on the scale-up of delamanid through GDF, please see the reports below:

Delamanid Order Status Report - 6 March 2019
Delamanid MSF Order Status Report - 6 March 2019

If you have any additional questions related to ordering delamanid, please address your inquires to your Country Support Officer or